Revvity Inc. stocks have been trading up by 8.14 percent after upbeat earnings guidance signaled stronger-than-expected growth.
Click Here for a Millionaire's POV on Trading RVTY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- KeyBanc lifted its price target on RVTY to $165 from $125 and kept an Overweight rating, pointing to better Q2 trends and strong AI-driven screening demand in Revvity’s Life Science business.
- A pending acquisition of France-based Human Cell Design will plug proprietary human pancreatic beta cell models into Revvity’s portfolio, sharpening its focus on diabetes, obesity and GLP‑1–related metabolic disease research.
- Baird boosted its RVTY price target to $144 from $131 and reiterated an Outperform call, while the name still carries an overall Overweight rating and a consensus target around the mid-$120s.
- RBC started coverage on Revvity with Sector Perform and a $135 target, flagging solid diagnostics and life sciences assets but questioning long-run 6%–8% organic growth.
- UBS shifted to Neutral on RVTY even as it raised its target to $140, above the current analyst mean, adding a more cautious voice to an otherwise bullish Street backdrop.
Live Update At 15:03:45 EDT: On Tuesday, September 15, 2026 Revvity Inc. stock [NYSE: RVTY] is trending up by 8.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RVTY has been grinding higher over the past few weeks, and the tape shows it. From 2026/08/21 to 2026/09/15, Revvity climbed from roughly $124 to about $139, with several higher lows along the way. That’s a clean uptrend, not a one-day pop.
The latest session opened near $129 and pushed to just under $140, closing at $138.95. Intraday, the 5‑minute chart shows tight trading between $133 and $139, with buyers steadily stepping in on dips. For active traders, that kind of orderly climb often signals accumulation rather than wild speculation.
More Breaking News
- CIEN Stock Draws Wave Of Upgrades On AI Networking Boom
- SDEV Stock Rockets On Heavy Volume As Traders Pile In
- Accenture Stock Jumps As AI Deals And New Units Fuel Momentum
- Rogers Corporation Stock Pops As Investor Day Catalysts Build
Fundamentally, Revvity printed about $729.7M in quarterly revenue, with an EBITDA near $191M and net income around $51.8M. Gross margin is a hefty 76.5%, but the profit margin is only about 8%, and the P/E near 59.5 says traders are paying up for future growth. RVTY’s balance sheet looks solid with a current ratio of 1.8 and debt-to-equity at 0.46, giving the company room to fund deals like Human Cell Design without stressing liquidity. For traders, this mix of strong margins, rich valuation, and rising price action screams “momentum — but watch your risk.”
Why Traders Are Watching RVTY Now
RVTY is suddenly on a lot more radar screens, and it’s not by accident. The stock’s steady climb has been backed by a string of bullish analyst moves and a targeted bet on one of the hottest themes in healthcare: GLP‑1 and metabolic disease.
KeyBanc’s decision to push its RVTY target to $165 from $125 is a big signal. They are seeing sustained improvement in Q2 trends, better end‑market spending, and more pre‑clinical cash flowing from pharma and biotech. For Revvity, that shows up as rising multi‑system orders per customer in its pre‑clinical-focused Life Science business, helped by AI‑driven screening demand. In trading terms, that’s not just a story — it’s a pipeline of repeat orders.
At the same time, Revvity is moving to acquire Human Cell Design in France. This gives RVTY proprietary human pancreatic beta cell models and related platforms. For traders, translate that into one thing: leverage to diabetes, obesity, and GLP‑1–related research. These are the same themes driving some of the biggest pharma runs in recent years.
Analysts are largely onboard. Baird bumped its RVTY target to $144 and stuck with Outperform. RBC’s Sector Perform at $135 and UBS’s Neutral at $140 sound cautious, but both targets sit above current consensus around the high-$120s. Even UBS, stepping back from a Buy, still sees upside from where the average Wall Street model sits. That mix of strong bulls and selective skeptics often creates exactly the kind of back‑and‑forth price action active traders like to trade.
Conclusion
For traders who study trends instead of headlines, RVTY is sending a clear message. The chart shows a controlled uptrend, the fundamentals show high margins and solid cash generation, and the news flow points to management leaning into secular growth themes like GLP‑1 and AI‑powered screening. Revvity’s planned Human Cell Design deal deepens its metabolic disease toolbox, while the balance sheet and free cash flow give it room to keep playing offense.
At the same time, the valuation is no bargain. A P/E near 60 means the market already expects Revvity to turn that GLP‑1 and diagnostics exposure into sustained growth. UBS and RBC are reminding traders that 6%–8% organic growth is not a given. If RVTY stumbles on execution or demand slows, that premium can compress fast.
This is where trading discipline matters. RVTY is a momentum name supported by rising targets — KeyBanc at $165, Baird at $144, others in the $135–$140 zone — but it’s still a tool, not a guarantee. As Tim Sykes likes to say, “Charts don’t lie, but traders do — so always trust the price action and cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” For anyone tracking Revvity, that means respecting both the upside narrative and the downside risk, and letting the chart — not the hype — drive the trading plan.
This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.